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Abstract
Background: Lymphatic filariasis and onchocerciasis are two chronic diseases mediated by parasitic filarial worms causing
long term disability and massive socioeconomic problems. Filariae are transmitted by blood-feeding mosquitoes that take
up the first stage larvae from an infected host and deliver it after maturation into infective stage to a new host. After closure
of vector control programs, disease control relies mainly on mass drug administration with drugs that are primarily effective
against first stage larvae and require many years of annual/biannual administration. Therefore, there is an urgent need for
alternative treatment ways, i.e. other effective drugs or vaccines.
Methodology/Principal Findings: Using the Litomosoides sigmodontis murine model of filariasis we demonstrate that
immunization with microfilariae together with the adjuvant alum prevents mice from developing high microfilaraemia after
challenge infection. Immunization achieved 70% to 100% protection in the peripheral blood and in the pleural space and
furthermore strongly reduced the microfilarial load in mice that remained microfilaraemic. Protection was associated with
the impairment of intrauterine filarial embryogenesis and with local and systemic microfilarial-specific host IgG, as well as
IFN-c secretion by host cells from the site of infection. Furthermore immunization significantly reduced adult worm burden.
Conclusions/Significance: Our results present a tool to understand the immunological basis of vaccine induced protection
in order to develop a microfilariae-based vaccine that reduces adult worm burden and prevents microfilaraemia, a powerful
weapon to stop transmission of filariasis.
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Introduction
Infections with filarial nematodes are classified among the
‘‘neglected tropical diseases’’ and cause serious public health
problems in the tropics and subtropics with more than 150 million
people infected and many more at risk. Lymphatic filariasis (LF)
caused by the filarial nematodes Wuchereria bancrofti and Brugia spp.
affects 120 million people with one third of them suffering from
clinical presentations of the infection, namely lymphedema of the
extremities and hydrocele, making LF the second-largest cause of
long-term disability [1].
Human filariasis is transmitted by blood feeding vectors that
ingest first stage larvae (microfilariae, Mf) from infected patients.
Within the vector, Mf undergo two obligatory molts to become
infective third stage larvae (L3). After their transmission to a new
host infectious L3 molt twice into adult worms, which mate and
release thousands of new Mf [2].
Current elimination strategies of the WHO such as the Global
Programme to Eliminate LF (GPELF [3]) or the African Programme
for Onchocerciasis Control (APOC [4]) are based on the mass drug
administration (MDA) of the microfilaricides ivermectin (IVM),
diethylcarbamazine and albendazole that have been successful in
reducing Mf-burden. However, only IVM and albendazole are used
in MDA programs against LF in Africa, because diethylcarbamazine
causes rapid death of Mf, thereby increasing chances of adverse
reactions, such as ocular damage in onchocerciasis [2]. In addition,
doxycycline has been introduced for individual drug administration
[5] directed against the obligate endosymbiotic Wolbachia bacteria of
the filariae [6,7]. Doxycycline inhibits filarial embryogenesis, and has
been proven to be macrofilaricidal and to halt or reduce pathology
[8,9]. However, doxycycline is contraindicated in children #9y e a r s
and pregnant woman and improvement of anti-wolbachial chemo-
therapy to be used in public health control programs is a focus of
ongoing research [2].
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programs in order to reduce infection and morbidity, certain
drawbacks have to be considered. IVM has only limited
macrofilaricidal efficacy [2] and repeated treatment for the life
of the adult worm (up to eight years) is needed in order to stop
transmission. Together with the limited logistics, especially in areas
with civil unrest, the occurrence of adverse events after treatment
such as scrotal pain or systemic inflammation can substantially
corrupt the degree of compliance to therapy [1]. Finally, emerging
resistance to drugs [10] reinforces the urgent need of alternative
ways of disease control.
Hence, besides drug therapy and vector control [11], the
development of a vaccine against filarial infections would be a
pivotal step towards the elimination of this disease [12]. As filarial
nematodes have a high reproductive capacity with a total daily
turnover of thousands of Mf in chronically infected human
individuals [13], a vaccine achieving substantial clearance of
circulating Mf would be a step towards stopping disease
transmission. At best, a vaccine would be used in conjunction
with MDA after Mf loads in a population were reduced either to
prevent re-infection or to prevent circulation of Mf in the blood,
particularly in areas of very high transmission.
Despite the severity of infection and the vast number of infected
people and individuals at risk, there is no vaccine against filarial
infections available [12,14]. Addressing this issue, various animal
immunization studies using different approaches have been
conducted. For example the group of Odile Bain used Litomosoides
sigmodontis L3 to immunize mice and achieved up to 58%
protection [15]. The protection was established within a few days
after challenge infection and was characterized by L3-specific
immunoglobulins, eosinophilia and high levels of IL-5. Lange and
colleagues used a similar approach to immunize mice with
Onchocerca volvulus L3 and also observed fast protection, which led
to reduction of the recovery rates by 54% to 77% between five and
28 days post challenge infection (p.i.), and this was also associated
with eosinophils and IL-5 [16]. In the experiments of Dixit el al
[17], immunization of Mastomys coucha with a fraction of adult B.
malayi extract reduced the recovery rate of adult worms by 85.7%.
Other groups used recombinant peptides instead of complete
extracts [18,19,20,21]. The immunization with B. malayi heavy
chain myosin for example generated a high level of protection
against challenge infection in jirds and M. coucha [21]. Different to
all these setups, Anand and colleagues used a cocktail of B. malayi
DNA to immunize mice and found high cytotoxcicity against B.
malayi Mf in immunized mice, associated with specific Ig and
increased IFN-c responses [22]. However, none of these studies
reported complete clearance of adults or Mf.
In the 1960s, Wenk and colleagues found that cotton rats
immunized with L. sigmodontis Mf had fewer blood-circulating Mf,
although adult worms were present [23,24,25]. In this study we
have taken this approach another step forward using the fully
permissive BALB/c mouse model to study filarial infections. In
this model with the advantage of greater access to immunological
tools, female L. sigmodontis worms release the Mf into the pleural
space of the thoracic cavity, the site of infection. From there they
migrate into the peripheral blood [26]. Here, we show that
immunization with Mf together with the adjuvant alum reduces
microfilaraemia by apparently inhibiting embryogenesis.
Materials and Methods
Animals
Eight - 12 week old female BALB/c wild type mice (Janvier, La
Genest St. Isle, France) were maintained under specific pathogen-
free conditions, according to animal welfare guidelines.
Ethics Statement
All animal experiments were approved by and conducted in
accordance with guidelines of the appropriate committee (Land-
esamt fu ¨r Natur, Umwelt und Verbraucherschutz, Ko ¨ln, Ger-
many).
Immunization
Mf were purified from the peripheral blood of infected cotton
rats on a Percoll gradient as described [27]. In brief, isoosmotic
Percoll (Sigma-Aldrich, Munich, Germany) was prepared by
mixing 9 parts of Percoll (density, 1.130 g/ml) with 1 part of
2.5 M D-sucrose (Sigma-Aldrich). Dilutions of the isoosmotic
Percoll in 0.25 M sucrose were made to obtain 25% and 30%
solutions. Three ml of both gradient dilutions were layered and the
peripheral blood diluted 1:2 in phosphate-buffered saline (PBS)
(PAA, Co ¨lbe, Germany) was placed on top. After centrifugation at
4006g for 30 min at room temperature (RT) without brakes, Mf
(between the 25% and 30% layers) were recovered and washed
twice with PBS and 1610
5 viable Mf per mouse were used for
each immunization. Injection was performed via different
administration routes as indicated in the text (see also Figure
S1). For Mf attenuation, 1610
6 Mf/ml were irradiated 40 min at
140 kV and 25 mA, corresponding to an absorbed dose of
400 Gray (Gy) at the Facility of Experimental Therapy of the
University Hospital Bonn. Microscopic analysis of irradiated Mf
confirmed their attenuation by monitoring their motility (data not
shown). For IVM (Merck, Darmstadt, Germany) treatment after
immunization, mice received 800 mg per kg mouse body weight.
For immunization with alum (Thermo Scientific, Bremen,
Germany), Mf were added slowly to the adjuvant to a final
adjuvant concentration of 25% and then mixed on an automatic
shaker at 1,000 rpm for 30 min. After this procedure Mf were
morphologically intact, however they were amotile and motility
was not reconstituted after 72 h at 37uC and 5% CO2, suggesting
Author Summary
Lymphatic filariasis is caused by parasitic filarial worms that
are transmitted by mosquitoes, requiring uptake of larvae
and distribution into the blood of the host. More than 120
million people are infected and about 30% of these
individuals suffer from clinical symptoms. Reduction in
transmission currently depends on mass drug administra-
tion, which has significantly reduced transmission rates
over the past years. However, despite repetitive rounds of
administration, transmission has not been eliminated
completely from endemic areas. In some infected individ-
uals the immune system can partially control the parasite,
such that a proportion of infected individuals remain
microfilaria-negative, despite the presence of adult worms.
Therefore mechanisms must exist that are able to combat
microfilaraemia. Identifying such mechanisms would help
to design vaccines against disease transmitting microfilar-
ial stages. Using the Litomosoides sigmodontis murine
model of filariasis research we show a successful immu-
nization against the blood-circulating larval stage that is
responsible for arthropod-dependent transmission of the
disease. Reduced microfilaraemia was associated with
impairment of worm embryogenesis, with systemic and
local microfilarial-specific host IgG and with IFN-c secretion
by host cells at the site of infection. These results raise
hope for developing a microfilariae-based vaccine, being a
pivotal step towards eradicating filariasis.
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suspension was intensively vortexed. For the sham injection
control mice received alum or PBS. In all experiments, second and
third immunization injections were performed two and three
weeks after the initial immunization.
Natural Infection
For challenge infection,infective L3 larvae were transmitted through
the bite of the vector mite Ornithonyssus bacoti as described [28]. Natural
infection was performed one week after the last immunization.
Mf Monitoring
Peripheral blood was taken from the tail vein and directly
transferred into 500 ml Hinkelmann solution (0.5% [wt/vol] eosin
Y, 0.5% [wt/vol] phenol (both Merck) and 0.185% [vol/vol]
formaldehyde (Sigma-Aldrich) in deionized water). After centrifu-
gation (5 min, 2506g) supernatant was discarded and pellet
suspended in 20 ml PBS before counting under the microscope
(406). For monitoring Mf in the pleural space, 20 ml from 1 ml
pleural space lavage (see section below) were added to 450 ml
Hinkelmann solution and treated as described for peripheral Mf.
Parasite Recovery
Mice were euthanized with Isofluran (Abbott, Wiesbaden,
Germany). Parasites and cells were harvested from the pleural space
by lavage with cold PBS. At 15 days p.i., L4 (L3/L4 molting around
day eight in BALB/c mice [29]) and at days 70 and 90 p.i. adults
(L4/adult molting around day 22 p.i. [29]) were separated from the
cells by 15 min sedimentation. For the embryogram each single
female worm was transferred into 80 ml PBS, cut into several pieces
and embryonic stages squeezed out of the uterus using a 1.5 ml
plastic tube and plastic pestle. The embryonic stages were stained by
adding 20 ml Hinkelmann solution and 10 ml of this preparation
(thus 10% of total uterine content of each analyzed female filariae)
were analyzed under the microscope. If present, three female worms
from each mouse were investigated. Damaged females, empty
females or females with only oocytes were excluded from analysis.
Ex vivo Restimulation
Ex vivo stimulations were performed at days 22, 70 or 90 p.i..
Lysis of red blood cells from the pleural space exudate cells was
done by 5 min incubation with trisammoniumchloride (Sigma-
Aldrich). Cells were washed twice with PBS, filtered through sterile
41 mm gaze (Bueckmann, Moenchengladbach, Germany), and
2.5610
5 cells per well in RPMI medium (supplemented with 10%
fetal calf serum, 1% L-glutamine, 1% penicillin/streptomycin, 1%
non-essential amino acids, 1% sodium bicarbonate, and 1%
sodium pyruvate (all PAA)) were stimulated with 5 mg/ml
concanavalin A (Sigma-Aldrich) in a 96 well plate (Greiner Bio-
One, Frickenhausen, Germany) or the respective worm extracts
for 72 h at 37uC and 5% CO2. For preparation of L. sigmodontis
extract, freshly isolated adult worms were rinsed in sterile PBS
before being mechanically minced. Insoluble material was
removed by centrifugation at 3006g for 10 min and 4uC. Protein
concentrations of crude extracts were determined using the
Advanced Protein Assay (Cytoskeleton, Denver, CO, USA). All
procedures were conducted under sterile conditions. L. sigmodontis
Mf extract was similarly prepared with sonicated (Bandelin
Electronics, Berlin, Germany) freshly isolated Mf.
Mf-Specific and Cytokine ELISA
Systemic Mf-specific IgG was measured from plasma of mice
directly before immunization injections (days 228, 214 and 27)
and in weekly intervals after infection (days 0, 7 and 14 p.i.). Blood
was taken submandibular from anesthetized (Ketanest, Medistar,
Ascheberg, Germany/Rompun, Bayer, Leverkusen, Germany)
mice. After centrifugation (5 min at 6,5006g), plasma was taken
and stored at 220uC until further usage. Mf-specific Ig of the
pleural space were measured from the supernatant of the pleural
space lavage at days 22 and 70 p.i.. Polysorb ELISA plates (Nunc,
Roskilde, Denmark) were coated overnight at 4uC with 10 mg/ml
of Mf crude extract in PBS at pH 9. After blocking 1 h with 1%
BSA-PBS (PAA), plates were washed with PBS containing 0.05%
Tween 20 (Sigma-Aldrich) and incubated for 2 h at RT with
either 50 ml of pleural space lavage or a 1:10 (IgE) or 1:1,000 (IgG)
dilution of plasma. After another washing step, biotinylated
detection antibody (BD Pharmingen, Heidelberg, Germany) was
added as recommended by the manufacturer. After a final wash,
alkaline phosphatase-conjugated streptavidin (Roche, Grenzach,
Germany) was added and tetramethylene benzidine (Carl Roth,
Karlsruhe, Germany) was used as substrate. The reaction was
stopped by adding 1 M H2SO4 (Merck) and the absorbance was
measured at 450 nm.
IFN-c (eBioscience, Frankfurt, Germany), IL-5 (BD Pharmin-
gen), IL-13, macrophage inflammatory protein 2 (MIP)-2a,
chemokine C-C motif ligand 5 (CCL5), granzyme B, eotaxin-1
and eotaxin-2 (R&D Systems, Wiesbaden, Germany) ELISA of the
pleural space lavage and the supernatants of restimulated cells
were performed according to manufacturer’s instructions.
Statistics
Statistical analyses were performed with GraphPad Prism 5.0
software (GraphPad Software, La Jolla, CA, USA), using the
Student’s unpaired t-test for parametric, the Mann Whitney t-test
(u-test) for nonparametric data and Welch’s correction for data
sets with different variances. Variances were tested with the
D’Agostino & Pearson omnibus normality test. P-values #0.05
were considered significant. Microfilaraemia, Ig kinetics and
cytokine responses after ex vivo restimulation were analyzed with
regular 2-way ANOVA and Bonferroni post tests. Data were
graphed with means 6 standard error of mean (SEM).
Results
Subcutaneous Immunization with Mf in Alum Prevents
Peripheral Microfilaraemia
Revisiting some of the known immunization protocols in animal
models, we immunized mice in various ways (for detailed
information see Figure S1). Initially, because Mf are mainly
located in the blood of the infected host, we immunized BALB/c
mice three times intravenously (i.v.) with 100,000 living Mf. This
injection resulted in a transient presence of Mf in the peripheral
blood lasting about two weeks (Figure S2A). After challenge
infection, natural Mf levels in the peripheral blood were monitored
from the onset of peripheral microfilaraemia at day 50 until the
end of patency around day 90 p.i.. This immunization neither
delayed the onset of natural microfilaraemia nor changed the Mf
levels in the peripheral blood after challenge infection compared to
control animals at any time point during patency (Figure 1A).
Next, since healthy Mf may modulate immune responses in the
immunized host, and in order to enrich the amount of
immunogenic material mice were treated after immunization with
the microfilaricide IVM, which suppresses the ability of Mf to
secrete immunomodulatory proteins [30] and inhibits their
neuromuscular control [31]. Accordingly, after IVM injection,
Mf disappeared from the peripheral blood within one day after
injection (Figure S2B). However, as observed for mice immunized
Immunization Reduces Microfilaraemia
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infection-challenged mice (Figure 1B).
According to the successful scheme originally used in cotton rats
[24], we then immunized mice first subcutaneously (s.c.), followed
by an intraperitoneal (i.p.) immunization two weeks later and an
i.v. immunization three weeks after primary immunization. As
with the two former schemes, this route of immunization failed to
protect mice and this was independent of the usage of either
healthy (Figure 1C) or irradiation-attenuated Mf (Figure 1D).
Finally, to investigate whether a standard adjuvant is able to
establish protective immunity, mice were then immunized three
times with 100,000 Mf together with the adjuvant alum. Due to
the viscosity of alum this immunization was performed s.c.. Mice
immunized with Mf in alum had significantly reduced numbers of
circulating Mf after challenge infection compared to control
animals throughout patency (P,0.05, Figure 2A). Furthermore,
the frequency of mice that became microfilaraemic until the end of
observation was significantly reduced in the immunized group
(P,0.05, Figure 2B).
Taken together, effective vaccination of 70–100% was only
observed in mice after s.c. immunization with Mf in alum, but not
after immunization with Mf alone, irrespective of the administra-
tion route, irradiation of Mf or IVM treatment of mice after
immunization. Consequently, all further experiments were
performed with 100,000 s.c.-administrated Mf in alum.
Immunization Blocks Embryogenesis of Female Worms
To investigate whether immunization inhibits the ability of
females to generate and release Mf or just hinders the Mf
migration into the blood, the pleural space lavage was analyzed for
the presence of Mf on days 70 and 90 p.i.. Figure 2C and D show,
that the number of Mf in the pleural space was significantly
reduced after immunization compared to the alum-treated control
group, the latter showing a wide range of microfilaraemia that is
well described for this model [28]. The few immunized mice that
were Mf
+ at day 70 p.i. had only low Mf levels with a mean of four
Mf compared to 226 Mf/20 ml lavage in the alum treated control
group (P,0.005, Figure 2C). Furthermore, at day 90 p.i. 90% of
the immunized mice were free of Mf with only one mouse having
five Mf/20 ml lavage. In contrast, 90% of control mice still
harbored Mf with a mean of 68 Mf/20 ml lavage (P,0.005,
Figure 2D). To rule out that alum itself influences the course of
infection, we compared mice injected s.c. with either alum or PBS
and did not find significant differences in the course of infection
(data not shown, 2-way ANOVA of peripheral microfilaraemia
P=0.4898, Welch-corrected t-test of pleural space Mf P=0.7377).
The reduction of Mf levels not only in the blood but also in the
pleural space suggested that either Mf were cleared immediately
after being released or the Mf output of female worms was reduced.
Consequently, the embryogenesis of female worms was analyzed.
During the filarial embryogenesis four main developmental stages
Figure 1. Immunization strategies that failed to protect mice from peripheral microfilaraemia. Mice were immunized with 100,000 Mf
either three times i.v. (A, B) or first s.c. followed by an i.p. and i.v. immunization (C, D). All control mice received PBS. L. sigmodontis challenge infection
was performed one week after the last immunization. (B) After immunization mice were treated i.v. with IVM. (D) Mice were immunized with
irradiated (400 Gy) Mf. Microfilaraemia was monitored throughout patency. Data obtained from single experiments with at least six mice per group
are shown. Two-way ANOVA (mean 6 SEM) was used for statistical analysis including both Mf
2 and Mf
+ mice.
doi:10.1371/journal.pntd.0001558.g001
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oocyte, divided egg (fulfilled first cell division), pretzel and stretched
Mf [32,33]. If present, three female worms from each mouse were
investigated. Empty females or females with only oocytes were
excluded from analysis. In the embryograms of three independent
experiments the percentage of those excluded females was similar
between immunized (33, 20 and 27%) and non-immunized mice
(16, 18, and 28%), indicating that immunization did not interfere
with insemination. At day 70 p.i. we found all stages to be present in
the uteri of female worms of control mice, whereas females of
immunized mice contained mainly the first two developmental
stages (oocyte and divided egg) but rarely pretzel stages (P,0.001)
and fully developed Mf (P,0.01, Figure 3E, see also Figure S4A).
To confirm this, any remaining worms were checked for the
presence or absence of later stages such as fully stretched Mf and
pretzel stages. Only two out of 23 female filariae were positive for
later stages in the Mf-vaccinated group (see also Figure S4A; 0/6
worms), whereas in the control group 25 of 31 females contained
stretched Mf (see also Figure S4A; 14/26 worms). Inhibition of
embryogenesis at day 70 p.i. was exemplarily documented by live
video analysis of the uteri of freshly isolated healthy females (video
S1, and Video S2). Finally, in an additional experiment inhibitionof
embryogenesis could already be observed at the beginning of
patency (day 56 p.i., see Figure S4B).
Taken together, these data suggest that immunization induces
the inhibition of larval development.
Figure 2. Mice immunized with Mf in alum have reduced numbers of Mf. Mice were immunized three times s.c. with 100,000 Mf in alum.
Control mice received alum alone. L. sigmodontis infection was performed one week after the last immunization. Microfilaraemia was monitored twice
a week throughout patency. (A) Kinetics of Mf load of sham-treated (dashed line) and immunized (black line) mice in the peripheral blood. One
representative of three independent experiments with ten mice per group is shown (2-way ANOVA, mean 6 SEM), including both Mf
2 and Mf
+ mice.
For additional experiments see figure S3A, B. (B) Percentage of Mf
+ mice of three independent experiments was analyzed using Student’s t-test. Each
mouse with peripheral Mf at any given time point was defined as Mf
+. (C, D) Mf burden in the pleural space days 70 (C) and 90 (D) p.i.. Graphs show
one representative of three (C) and two (D) independent experiments (at least seven mice each group, see also Figure S3C–E) and were analyzed with
Welch-corrected t-test. Numbers below the symbols indicate the number of Mf
+ mice (median, * P,0.05, ** P,0.005).
doi:10.1371/journal.pntd.0001558.g002
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Cross reactive protection with respect to other developmental
stages is known for immunization with L. sigmodontis L3. Thus, we
asked whether Mf immunization may also affect stages other than
the Mf. Analysis of the L4 burden at day 15 p.i. and adult burden at
day56p.i.showed that immunized micehadsimilar worm numbers
as control animals (Figure 4A, B). However, at day 70 (P,0.005,
Figure 4C) and 90 p.i. (P,0.0001, Figure 4D) immunized mice
contained significantly fewer adult worms and this reduction was
associated with decreased numbers of both males and females, as
the gender balance was similar in immunized and control mice
(Figure 4E). Male and female worms did not differ in length to the
corresponding worms of control mice (Figure 4F, G).
Taken together, our data show that immunization with
100,000 Mf in alum not only inhibited microfilaraemia, but also
reduced adult worm burden at later time points.
Humoral and Cellular Immune Responses Induced by
Immunization
To investigate whether immunization-induced Mf-specific Ig
responses were associated with protection, Mf-specific IgE, IgG1
and IgG2 levels were measured in the plasma and pleural space
lavage at different time points throughout immunization and
infection. As Figure 5A and B illustrate, the immunization induced
an Mf-specific humoral response and both IgG1 and IgG2
antibodies were elevated in the blood. The most prominent
increase was observed after the boost immunizations, as indicated
by the levels seven days before the challenge infection. A
comparison of both immunized groups (infected vs. uninfected)
revealed that these humoral responses were not further enhanced
by the infection itself. The same picture was found at the site of
infection with Mf-specific IgG1 and IgG2 levels being significantly
elevated in immunized mice compared to controls on day 22
(P,0.001, Figure 5C, D) as well as on day 70 p.i. (P,0.001,
Figure 5E, F). Albeit the differences in IgG1 levels remained
significantly higher in immunized mice at day 70 p.i., the IgG1
levels of infected but non-immunized mice increased on days 28
and 42 (Figure S6C, D) compared to day 22 p.i. (Figure S6A, B).
This however indicates a Th2 shift induced by the parasite itself
and is well-known for primary infected BALB/c mice [34,35].
The amount of Mf-specific IgE was not increased at day 22 p.i.
in the pleural space of immunized mice (mean OD of 0.047)
Figure 3. Immunization inhibits embryogenesis in female worms. Mice were immunized three times s.c. with 100,000 Mf in alum. Control
mice received alum alone. L. sigmodontis challenge infection was performed one week after the last immunization. Seventy days after infection
female worms were analyzed for their embryonic stages. Representative pictures of oocyte (A; micron bar 10 mm), divided egg (B; 10 mm), pretzel
stage (C; 15 mm) and stretched Mf (D; 30 mm) are shown. (E) Embryogram illustrating the composition of embryonic stages in female worms. If
present, three female worms of each mouse were investigated (27 females in the control group, 28 females from the immunized group, additional
experiments see Figure S4). Statistical analysis was performed with Mann-Whitney U-test (mean 6 SEM, ** P,0.01, *** P,0.001).
doi:10.1371/journal.pntd.0001558.g003
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during infection, Mf-specific IgE was elevated in the blood of
immunized mice with a mean OD of 0.121 (day 28 p.i.) and 0.187
(day 42 p.i.) in immunized mice, and a mean OD of 0.043 and
0.050 in control mice, respectively. However, these levels of Mf-
specific IgE clearly did not reach the IgE levels of chronically
infected mice (OD on day 100 p.i. 1.683; single experiment, data
not shown), suggesting that immunization per se does not lead to a
strong IgE induction.
To classify cellular responses, we analyzed major cell popula-
tions in the pleural space lavage by flow cytometry. However, no
consistent differences were observed (Table S1). We also measured
various cytokines in the pleural space at day 22 p.i.. Since
eosinophils are known effector cells in helminth infections [36], we
measured molecules involved in eosinophil recruitment or activity,
i.e IL-13, MIP-2a, CCL5, granzyme B, eotaxin-1 and eotaxin-2.
Results from three independent experiments did not reveal any
significant differences between immunized mice and control
animals (data not shown). However, analysis of hallmark cytokines
IL-5 and IFN-c of type 1 and 2 immunity showed that immunized
mice had significant more IFN-c in the pleural space of the
thoracic cavity (P,0.001), whereas level of IL-5 were low
irrespective of the immunization (Figure 6A). A similar picture
was observed when cells recovered from the pleural space were
restimulated with worm extracts (Figure 6B, C). Strikingly, 22 days
p.i., a time point when parasites are already present in the pleural
space, only cells of immunized mice secreted IFN-c regardless of
whether they were infected or not. This effect was seen after
specific restimulation with crude extract of adult worms and Mf, as
well as with nonspecific stimulation by concanavalin A (P,0.001,
Figure 6B). Although less pronounced, enhanced IFN-c responses
after restimulation were also present throughout patency (Figure
S7A, B). Different to IFN-c, the IL-5 responses were dependent on
the infection itself, as only cells from infected mice secreted IL-5
after restimulation irrespective of immunization (Figure 6C, Figure
S7C, D).
Discussion
Current public health control of human filarial infections relies
on chemotherapy provided by MDA programs. Antifilarial drug
therapy has to be implemented for years with high coverage,
incurring high logistical costs and the emergence of drug resistance
is a potential threat [12]. Thus, a vaccine that results in the
reduction of parasite burden would complement the MDA efforts,
as suggested for other neglected tropical diseases [37] and that
would be complementary step towards elimination of the diseases.
The present study describes a successful immunization protocol
against L. sigmodontis Mf in the murine model of filariasis, which
additionally resulted in a reduced adult worm burden. Subcuta-
neous immunization with Mf in alum prevented the onset of
microfilaraemia after challenge infection in the majority of mice.
Reduced Mf loads were observed in the peripheral blood and at
the site of infection in conjunction with intrauterine inhibition of
embryogenesis. Protection was further associated with systemic
and local Mf-specific IgG and IFN-c secretion of pleural space
exudate cells.
In mouse models the adjuvant alum is often administered i.p.
and this route has been referred to establish ‘‘systemic’’ responses
in contrast to the ‘‘local’’ s.c. route [38]. Interestingly, we found
Figure 4. Immunization reduces adult worm burden, but does not affect their development. Mice were immunized three times s.c. with
100,000 Mf in alum. Control mice received alum alone. L. sigmodontis challenge infection was performed one week after the last immunization.
Numbers of worms on days 15 (A), 56 (B), 70 (C) and 90 (D) p.i. (additional experiments see Figure S5A–C), gender balance (E) (individual experiments
see Figure S5D, E), as well as length of males (F) and females (G) at day 90 p.i. (10/90 percentile, outliers are indicated, individual experiments see
Figure S5F–I) were analyzed with Student’s t-test (** P,0.01, *** P,0.001).
doi:10.1371/journal.pntd.0001558.g004
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and both systemic i.p. and i.v. routes to be able to reduce
microfilaraemia (Figure 1). As systemic immunizations have been
reported to induce tolerance rather than immunity [39], out of the
protocols tested in this study, only the s.c. immunization was able
to immunize mice successfully against L. sigmodontis Mf. The s.c.
immunization would also be a route, which is best applicable to
humans.
It is known that immunization with irradiated L3 stages reduces
the recovery rate of larvae in the pleural space [40]. However,
immunization with Mf did not render mice less susceptible for
infection per se, as the worm burden did not differ on day 15 p.i..
The short time between immunization and challenge infection
might explain the absence of enhanced immunity against
incoming L3. The observation that the adult worm burden
remained similar in both groups until the onset of patency at day
56 p.i., may suggest that the accessibility of Mf in the pleural space
of the thoracic cavity could be a critical step in initiating the
responses that affect the adult filariae. However, only one
experiment was performed on day 56 and a more detailed
Figure 5. Immunization induces Mf-specific IgG1 and IgG2. Mice were immunized three times s.c. with 100,000 Mf in alum (Al-Mf/naı ¨ve, Al-
Mf/Inf). Control mice received alum alone (Al/naı ¨ve, Al/Inf). L. sigmodontis challenge infection was performed one week after the last immunization
(Al/Inf, Al-Mf/Inf) or left uninfected (Al/naı ¨ve, Al-Mf/naı ¨ve). Plasma levels of Mf-specific IgG1 (A) and IgG2a/b (B) were measured. Two-way ANOVA was
used for statistical analysis, day 0 indicates day of challenge infection. Asterisks indicate significant differences between the immunized and infected,
and the corresponding control group (*** P,0.001) and pound signs between the immunized but uninfected, and the corresponding control group
(
# P,0.05,
## P,0.01,
### P,0.001). (C–F) Pleural space lavage was analyzed for specific IgG1 and IgG2a/b on days 22 (C, D) and 70 p.i. (E, F). Data
analyzed with Welch-corrected t-test (mean, *** P,0.001). Graphs show representatives of three independent experiments with eight to ten mice
each group (additional experiments see Figure S6A, B, E–J).
doi:10.1371/journal.pntd.0001558.g005
Figure 6. Immunization enhances IFN-c responses. (A) At day 22 p.i. the pleural lavage was analyzed for IL-5 and IFN-c. Combined data of three
independent experiments with five mice each group are shown. (B, C) At day 22 p.i. cells from the site of infection were restimulated for 72 h with
5 mg/ml Concanavalin A (ConA), 100 mg/ml complete adult (Ls) or microfilarial (Mf) crude extract of L. sigmodontis and IFN-c (B) and IL-5 (C) secretion
were measured (mean 6 SEM). Representative data of two independent experiments with five mice each group. Analysis was done using the 2-way
ANOVA, for significances see text.
doi:10.1371/journal.pntd.0001558.g006
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the time point when adulticidal immune responses are effective.
Interestingly, at later time points, namely on days 70 and 90 p.i.,
we could observe a reduced worm burden in immunized mice
compared to the controls. This reduction was seen with both male
and female worms, suggesting effector mechanisms not only acting
against intrauterine Mf in female worms, but against target
structures of adult worms. In line with this, different developmen-
tal stages of filariae share many molecular structures [41] and
cross-reactive immunization effects are documented for filarial
immunizations [19,42]. Importantly, it is unlikely that the lower
worm burden observed on days 70 and 90 p.i. is the reason for
reduced microfilaraemia in immunized mice, because all immu-
nized mice contained male and female worms and it has been
shown that even a few fecund females can establish peripheral
microfilaraemia [43].
Inhibition of embryogenesis in immunized mice was further
indicated by the reduced number of Mf in the pleural space and,
more importantly, the presence of embryonic stages that had not
developed beyond several divisions of the fertilized oocytes. This is
in contrast to Wenk and colleagues who found fully developed Mf
in the uterus of female worms and in the pleural space of infected
and Mf-immunized cotton rats [23]. The differences between both
animal models in the mode of Mf reduction may be due to
different susceptibilities of the hosts to L. sigmodontis. Both, BALB/c
mouse and the cotton rat develop patent infection, but BALB/c
mice clear the infection after 3–4 months, whereas the cotton rat is
the natural host and can harbor filarial parasites for years [29].
This is the general downside of using laboratory mice for L.
sigmodontis infection rather than the natural host; however the
advantage is that cytokine responses can be measured and
associated with protection, and for future studies cytokine deficient
mice may answer further questions about the essentiality of key
cytokines for vaccination success.
In our experiments, immunization induced Mf-specific IgG1
and IgG2 antibodies, present throughout the whole infection
including patency, were associated with protection. Because
protective responses induced by immunization often rely on
protective antibodies [44] and the importance of B cells in
promoting immune responses against filarial Mf is well document-
ed for the murine model of filariasis [45,46], we analyzed the
frequency and total number of pleural space B1 and B2 B cells by
flow cytometry, but found no consistent differences between
immunized and non-immunized mice (Suppl. Table 1), suggesting
differences in B cell activation rather than in total B cell numbers.
Interestingly, despite a strong antibody production female worms
of immunized mice appeared morphologically as intact as those in
non-immunized control mice. Furthermore we did not find any
host cells within the female worms. These two findings suggest a
blockade of embryonic development, rather than a cell-dependent
destruction of the embryonic stages. In our experiments, Mf-
specific IgGs may have entered the female worm uterus and bound
to the developing early developmental stages, thereby hindering
their further growth in an Ig-dependent, but cell-independent
manner. Indeed, it is known that filarial-infected humans produce
filarial-specific Ig that is able to bind early intrauterine filarial
stages, as shown by using sera of chronic LF patients against
isolated intrauterine Mf stages from the filariae Setaria digitata [47].
Another possibility for cell-independent, Ig-mediated responses is
the activation of the complement cascade resulting in the
formation of the membrane attack complex (MAC), due to
insertion of complement proteins into a phospholipid bilayer [48].
Although there is as yet no evidence for MAC formation in the
sheath of adult nematodes, earlier developmental stages may be
more sensitive to MAC formation. The next step to clarify the role
of antibodies in the establishment of immunization-induced
protection would be the verification of embryonic stage-bound
Mf-specific Ig, e.g. by immunohistochemistry. Furthermore,
experiments with mice having a defect in immunoglobulin
production would give important insights into the relevance of
Ig for impairment of embryogenesis. Also, a possible IgE reaction
to the immunization has to be elucidated. We did not observe a
strong IgE response after immunization and infection in the blood
nor at the site of infection. However, future experiments should
clarify how chronically infected mice that already have Mf-specific
IgE respond to immunization. In humans, a vaccination may be
favourable one month after IVM treatment, when individuals have
no skin or blood Mf, as the risk of urticaria due to immune attack
on remaining Mf would be at its minimum.
IFN-c and IL-5 are well known players in innate, adaptive and
vaccine-induced immunity against helminths [49], with the
adaptive type 2 response referred to as ‘‘typical’’ for helminth
infections [50]. We found that immunization was associated with
strong IFN-c responses, mirrored by increased levels in the pleural
space and after restimulation of pleural exudate cells. The
importance of IFN-c production in immune responses against
Mf in permissive BALB/c mice is underlined by several findings.
IFN-c
2/2 mice have increased numbers of circulating L.
sigmodontis Mf compared to the wild type littermates [51]. In
addition it has been shown that IFN-c RNA levels of restimulated
splenocytes obtained from L. sigmodontis-infected BALB/c mice are
strongly increased within days after the beginning of patency [52].
These observations may reflect the moderate increase in IFN-c
production also in non-immunized mice upon natural infection
and the less pronounced but still significant differences in IFN-c
between immunized and non-immunized mice during patency
(Figure S7A, B). Furthermore, it is known that injected B. malayi
Mf, but not implanted adult stages induce IFN-c and Th-1-
assiociated IgG2a in BALB/c mice [53]. IFN-c is an inducer of
IgG2a [54] therefore it is most likely that in our experiments, Mf-
induced IFN-c has promoted the secretion of IgG2. Importantly,
induction of IFN-c is not in conflict with the use of the adjuvant
alum, which is generally referred as Th2-promoting, because
recent findings have shown that alum also can influence
proliferation and IFN-c production of CD8
+ T cells [55].
Furthermore, Toll-like receptor agonists have been found to be
able to bias alum towards a mixed Th1/Th2 response [56]. L.
sigmodontis, like many other filariae contains endosymbiotic
Wolbachia bacteria that are recognized by Toll-like receptors [57].
Although IL-5 responses did not differ between immunized and
control mice, this cytokine may also play a role for the overall
effect of immunization in the infected mice. It may even be
possible that the effect of immunization, although predominated
by IFN-c, may be dependent on at least baseline levels of IL-5,
since this cytokine has been shown to be important for both adult
worm and Mf containment in L. sigmodontis infection in our earlier
reports [58,59]. Future immunization experiments with BALB/c
mice defective for IFN-c or IL-5 responses will shed more light on
the importance of both key cytokines for the inhibition of
embryogenesis.
Taken together, the immunization scheme presented in this study
demonstrates the feasibility of an immunization that is directed against
the Mf stage, leading to protection against peripheral microfilaraemia
with an efficacy of up to 100%. The IFN-c that has been induced by
the immunization suggests a shift towards a Th1-like milieu in the host
that may furthermore promote direct or indirect responses against the
Mf during patency, possibly through IFN-c-promoted IgG2a. It is
known for human LF that there is a threshold for Mf density in the
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infective bites is needed to produce a patent infection [60]. We
hypothesize that the reduction of circulating peripheral Mf at the level
we observed might prevent transmission.
The study presented here contributes to the understanding of
the immune mechanisms needed to develop a vaccine against
filarial parasites. Whereas the use of Mf recovered from infected
humans would be costly and the number of Mf limited, even
disregarding the potential transmission of other infections, our
data may serve for a better understanding of the nature of
protective Mf vaccination. Future assessments should address the
characterization of microfilarial molecular subunits that account
for this protection, as the growing fields of helminth genomics [61]
and systems biology [62] may predict such potential Mf-related
vaccine candidates. Administration of only a subunit vaccine may
also avoid vaccination with tolerogenic molecules contained within
the Mf and lead to better efficacy of protection.
Supporting Information
Figure S1 Immunization schemes. Figure shows schedule of
immunization, challenge and analysis. Table shows detailed
information of all immunization experiments mentioned in the text.
(TIF)
Figure S2 Kinetic of i.v.-injected Mf in the peripheral
blood. 100,000 Mf were injected i.v. into the tail vein and Mf in
the peripheral blood was monitored daily. (A) Representative data
of two independent injections with seven mice per group (mean 6
SEM). (B) One hour after injection mice were treated with IVM at
800 mg per kg body weight. One representative of two indepen-
dent injections with eight mice per group is shown (mean 6 SEM).
(TIF)
Figure S3 Additional experiments showing reduced Mf
load. Mice were immunized three times s.c. with 100,000 Mf in
alum. Control mice received alum alone. L. sigmodontis infection
was performed one week after the last immunization. (A, B)
Kinetics of Mf load of control (dashed line) and immunized (black
line) mice in the peripheral blood of two additional experiments
with ten mice per group each experiment (2-way ANOVA, mean
6 SEM), including Mf
2 and Mf
+ mice. (C–E) Mf burden in the
pleural space at days 70 (C, D) and day 90 (E) p.i., analyzed with
Welch-corrected t-test (mean, * P,0.05). Numbers below the
symbols indicate number of Mf
+ mice in the shown experiment.
(TIF)
Figure S4 Additional experiments illustrating inhibited
embryogenesis in female worms of immunized mice.
Mice were immunized three times s.c. with 100,000 Mf in alum.
Control mice received alum alone. L. sigmodontis challenge infection
was performed one week after the last immunization. Seventy (A)
and 56 days (B) after infection female worms were analyzed for their
embryonic stages. Analysis was performed with Mann-Whitney u-
test (mean 6 SEM, * P,0.05, ** P,0.01, *** P,0.001).
(TIF)
Figure S5 Additional data illustrating that immuniza-
tion reduces adult worm burden, but does not affect
their development. Mice were immunized three times s.c. with
100,000 Mf in alum. Control mice received alum alone. L. sigmodontis
challenge infection was performed one week after the last immuni-
zation. Numbers of worms at days 70 (A) and 90 p.i. (B, C), gender
balance of worms (D, E) and length of males (F, G) and females (H, I)
at day 90 p.i. (10/90 percentile, outliers are indicated) were analyzed
with Student’s t-test (mean 6 SEM, * P,0.05, *** P,0.001).
(TIF)
Figure S6 Additional data confirming enhanced Mf-
specific IgG1 and IgG2. Mice were immunized three times s.c.
with 100,000 Mf in alum (Al-Mf/naı ¨ve, Al-Mf/Inf). Control mice
received alum alone (Al/naı ¨ve, Al/Inf). L. sigmodontis challenge
infection was performed one week after the last immunization
(Al/Inf, Al-Mf/Inf) or left uninfected (Al/naı ¨ve, Al-Mf/naı ¨ve).
Plasma levels of Mf-specific IgG1 (A) and IgG2a/b (B) were
measured. Asterisks indicate significant differences between the
immunized and infected, and the corresponding control group (*
P,0.05, ** P,0.01, *** P,0.001) and pound signs between the
immunized but not infected, and the corresponding control group
(
# P,0.05,
## P,0.01,
### P,0.001). (C, D) Plasma Mf-
specific IgG1 and IgG2 at days 28 and 42 p.i. measured in a
single experiment and analyzed with Student’s t-test (mean 6
SEM, *** P,0.001). (E–J) Pleural space lavage was analyzed for
specific IgG1 and IgG2a/b at days 22 (E–H) and 70 p.i. (I, J).
Data were analyzed with the Welch-corrected t-test (mean, **
P,0.01, *** P,0.001).
(TIF)
Figure S7 IFN-c and IL-5 responses of pleural space
exudate cells. Cells from the site of infection were restimulated
72 h with 5 mg/ml Concanavalin A (ConA) or 100 mg/ml
complete adult crude extract of L. sigmodontis (Ls) at day 70 (A,
C) or day 90 p.i. (B, D). Combined data from two independent
experiments are shown. Analysis was done with 2-way ANOVA
(mean 6 SEM, * P,0.05).
(TIF)
Table S1 Flow cytometric analysis of pleural space
exudate cells 15, 22, 70 and 90 days p.i.. Mice were
immunized three times s.c. with 100,000 Mf in alum. Control
mice received alum alone. L. sigmodontis challenge infection was
performed one week after last immunization. Percentages (A) and
absolute numbers (B) for dendritic cells (DC), macrophages (MO),
B-cells (BC) and B2 B-cells (B2 BC), T-cells (TC) and eosinophils
(EO) are shown. Staining was performed according to standard
protocols with fluorochrome-conjugated antibodies to the surface
markers F4/80, SiglecF, CD3e, CD11c, CD19, and CD23, used
as recommended by the manufacturers (eBioscence, BD Pharmin-
gen). ‘‘-’’ indicates that no data are available for that time point.
(XLS)
Video S1 Live in-uteri analysis of larval development in
control mice. One representative adult female worm isolated
from the pleural space of an alum-treated control mouse was
placed on a microscope slide and filmed with the microscope
analysis software Diskus 4.6 (Hilger, Koenigswinter, Germany).
Living and moving Mf in the uterus can be seen.
(MOV)
Video S2 Live in-uteri analysis of larval development in
immunized mice. One representative adult female worm
isolated from the pleural space of an Mf-alum immunized mouse
was placed on a microscope slide and filmed with the microscope
analysis software Diskus 4.6 (Hilger, Koenigswinter, Germany).
Divided eggs stages in the uterus can be seen (indicated by the
arrow).
(MOV)
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